EDIT News and Press, Editas Medicine Inc. From 11/03/23

2023-11-03 10:23:43 ET More on Editas Medicine Editas Medicine: A Mispriced Contender In The Gene Editing Arena Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript) ...

2023-11-03 07:03:16 ET More on Editas Medicine Editas Medicine: A Mispriced Contender In The Gene Editing Arena Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript) ...

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...

Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar Granted Vor Bio a non-exclusive license for Cas9 patents for ex vivo HSC therap...

Editas Medicine Inc. (EDIT) is expected to report $-0.64 for Q3 2023

2023-11-02 11:27:23 ET More on Editas Medicine Editas Medicine: A Mispriced Contender In The Gene Editing Arena Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript) ...

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children’s to present EDIT-301 clinical data at ASH on Monday, December 11 CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Edit...

2023-10-31 12:46:31 ET More on Eli Lilly Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Eli Lilly: Do Not Chase This Stock Over The Cliff ...

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2...

2023-10-24 08:05:14 ET More on Beam, CRISPR, etc. Beam: Opportunity Based On SCD Data Readout In 2024 Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy Editas Medicine: A Mispriced Contender In The Gene Editing Arena Beam extend...